CHWY vs GIPL vs NEOG Stock Comparison

Chewy, Global Innovative Platforms and Neogen Prices as of Oct 27, 2026 Peers: Industry group
CHWY Chewy, Inc.
$21.51 +17.6% 1M -37.9% 1Y
Market cap
$8.37B
P/E
30.6x
Revenue (TTM)
$13.07B
Div. yield
–
Packaged Foods Consumer Staples
7 wins
NEOG Neogen Corp
$12.47 -9.4% 1M +100.8% 1Y
Market cap
$2.65B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

9 decided of 12

Chewy leads on 7 of the 12 questions below (Chewy 7, Neogen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCHWYGIPLNEOGLeader
Larger companyMarket capitalisation $8.37B $24.88M $2.65B CHWY
Cheaper on earningsLower P/E, profitable companies only 30.6x -36.0x -47.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 28.3x — 39.0x CHWY
Faster revenue growthRevenue growth, trailing twelve months +5.9% — -0.3% CHWY
More profitableNet margin, trailing twelve months 2.1% -361.7% -6.3% CHWY
Better return on capitalReturn on invested capital — — -0.2% –
Less leveragedLower net debt / EBITDA 0.0x 0.4x 5.4x CHWY
Higher dividend yieldTrailing dividend yield 0.00% — 0.00% –
Better 1-year returnPrice return, last 12 months -37.9% -37.5% +100.8% NEOG
Better 5-year returnAnnualised price return, 5 years -21.6%/yr -36.9%/yr -21.4%/yr NEOG
Less volatileAnnualised volatility, 1 year 47.2% 271.4% 55.6% CHWY
Higher overall scoreMean of the five percentile scores vs peers 70/100 55/100 58/100 CHWY

Percentile Scorecard

CHWYGIPLNEOG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCHWYGIPLNEOG
Valuation 56 #20 of 44 62 #241 of 625 71 #66 of 227
Growth 90 #5 of 40 27 #442 of 602 50 #110 of 219
Profitability 57 #17 of 38 39 #335 of 551 62 #79 of 206
Financial Health 62 #18 of 46 98 #12 of 656 46 #128 of 238
Shareholder Returns 86 #5 of 30 50 #183 of 365 58 #57 of 134
Overall 70 55 58
  • CHWY ranked among 47 companies in Branded Foods
  • GIPL ranked among 672 companies in Pharmaceuticals and Biotechnology
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCHWYGIPLNEOGSPY
1 month +17.6%0.0%-9.4% -0.2%
3 months -6.2%0.0%+35.7% +3.9%
6 months -15.9%-3.8%+33.5% +8.2%
Year to date -34.9%+354.5%+78.4% +12.9%
1 year -37.9%-37.5%+100.8% +12.3%
3 years +19.4%-52.4%-18.6% +87.4%
3 years, per year +6.1%-21.9%-6.6% +23.3%
5 years -70.4%-90.0%-69.9% +67.9%
5 years, per year -21.6%-36.9%-21.4% +10.9%
10 years —-82.9%-35.8% +261.1%
10 years, per year —-16.2%-4.3% +13.7%

Risk

MeasureCHWYGIPLNEOGSPY
Volatility, 1Y 47.2%271.4%55.6% 12.7%
Downside volatility, 1Y 47.8%—46.5% 12.7%
Beta vs S&P 500, 1Y 0.782.271.45 1.00
Return / volatility, 1Y -0.80-0.141.81 0.97
Max drawdown, 5Y -81.2%-98.0%-90.6% -25.4%
From 52-week high -39.2%-49.5%-10.8% -1.2%
52-week high $35.37$0.99$13.98 $779.14
52-week low $17.51$0.11$5.41 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCHWYGIPLNEOG
P/E now vs peer median 31.9xmedian 22.3x -36.0xmedian 17.2x -48.5xmedian 29.6x
P/S now vs peer median 0.7xmedian 0.7x 132.9xmedian 9.0x 3.1xmedian 2.9x
EV/EBITDA now vs peer median 18.2xmedian 12.3x -39.5xmedian 16.3x 30.0xmedian 17.4x
P/FCF now vs peer median 15.2xmedian 13.8x -32.5xmedian 18.7x 54.7xmedian 22.3x
P/B now vs peer median 23.3xmedian 1.5x 46.8xmedian 2.2x 1.3xmedian 2.3x
PEG now vs peer median 0.42median 0.57 -0.57median 0.33 1.73median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCHWYGIPLNEOG
Revenue $13.07B $187.20K $883.99M
Gross profit $3.91B – $418.98M
Operating income $328.20M -$677.04K -$7.38M
Net income $273.70M -$677.04K -$56.10M
Free cash flow $568.10M -$766.04K $49.80M
R&D – $377.99K $19.76M
EPS (diluted) $0.67 $-0.02 $-0.26
Cash & equivalents $611.00M $244.24K $172.00M
Total debt $591.70M $8.62K $774.20M
Shares (diluted) 410.10M 44.54M 218.10M
Enterprise value $5.65B $24.27M $1.99B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCHWYGIPLNEOG
P/E 31.9x -36.0x -48.5x
P/FCF 15.2x -32.5x 54.7x
P/Operating cash flow 12.0x -35.0x 31.9x
P/S 0.7x 132.9x 3.1x
P/B 23.3x 46.8x 1.3x
P/Tangible book 39.1x 47.1x 3.4x
EV/EBITDA 18.2x -39.5x 30.0x
EV/EBIT 26.2x -36.4x -450.7x
EV/Revenue 0.7x 131.6x 3.8x
EV/FCF 15.2x -32.2x 66.8x
EV/Operating cash flow 12.0x -34.7x 39.0x
PEG (3Y EPS CAGR) 0.42 -0.57 1.73

Growth

14 metrics
MetricCHWYGIPLNEOG
Revenue growth (1Y) 5.9% – -0.3%
Revenue CAGR (3Y) 6.4% – -1.3%
Gross profit growth (1Y) 7.6% – 1.8%
Gross profit CAGR (3Y) 8.5% – -3.1%
Operating income growth (1Y) 102.0% -20.9% 99.3%
Operating income CAGR (3Y) 139.1% -51.6% -29.0%
Net income growth (1Y) 81.1% -20.9% 94.6%
Net income CAGR (3Y) 73.8% -51.6% -28.3%
EPS growth (1Y) 89.2% -9.8% 94.6%
EPS CAGR (3Y) 76.8% 63.5% -28.0%
Operating cash flow growth (1Y) 17.3% 15.8% -1.9%
Operating cash flow CAGR (3Y) 10.9% -96.8% 2.9%
Free cash flow growth (1Y) 22.7% 9.2% 1,631%
Free cash flow CAGR (3Y) 18.6% -101.8% 126.1%

Profitability

14 metrics
MetricCHWYGIPLNEOG
Gross margin 29.9% – 47.4%
EBITDA margin 3.6% -333.4% 12.5%
Operating margin 2.5% -361.7% -0.8%
Pretax margin 2.7% -361.7% -7.7%
Net margin 2.1% -361.7% -6.3%
FCF margin 4.3% -409.2% 5.6%
Operating cash flow margin 5.5% -379.8% 9.6%
Return on equity 68.9% -120.8% -2.7%
Return on assets 7.8% -119.7% -1.7%
Return on invested capital – – -0.2%
Return on capital employed 24.9% -121.4% -0.2%
Asset turnover 3.7x 0.3x 0.3x
Cash conversion (OCF / net income) 2.6x 1.1x -1.5x
Stock comp / revenue 2.3% – 1.3%

Financial Health

11 metrics
MetricCHWYGIPLNEOG
Debt / assets 15.8% 1.0% 23.4%
Debt / equity 1.6x 0.0x 0.4x
Net debt / EBITDA 0.0x 0.4x 5.4x
Debt / FCF 1.0x 0.0x 15.5x
Liabilities / assets 90.1% 1.4% 36.8%
Equity / assets 9.9% 98.6% 63.2%
Interest coverage – – –
Current ratio 0.8x 34.7x 3.9x
Quick ratio 0.4x 33.2x 2.1x
Cash ratio 0.3x 31.3x 1.2x
Altman Z-score 4.76 1,908 1.52

Shareholder Returns

7 metrics
MetricCHWYGIPLNEOG
Dividend yield – – –
Net buyback yield 5.9% -3.2% -0.1%
Shareholder yield 5.9% -3.2% -0.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCHWYGIPLNEOG
Forward P/E 28.3xFY2026 – 39.0xFY2026
EPS, next fiscal year $0.76FY2026 – $0.32FY2026
EPS growth, next FY +46.2%FY2026 – 0.0%FY2026
EPS growth, the year after +47.4% – +31.3%
Revenue, next fiscal year $12.87BFY2026 – $847.28MFY2026
Revenue growth, next FY +2.1%FY2026 – -2.7%FY2026
Revenue growth, the year after +5.5% – -1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCHWYGIPLNEOG
Held by institutions 100.0% – 100.0%
Institutions holding 511 – 315
Change in shares held, QoQ -0.4% – +1.6%
Institutions buying 277 – 151
Institutions selling 155 – 106
Buyers to sellers 1.79 – 1.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CHWYGIPLNEOG
CHWY 1.00 0.01 0.10
GIPL 0.01 1.00 0.01
NEOG 0.10 0.01 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CHWY, GIPL and NEOG?

Chewy (CHWY) is the largest by market capitalisation: Chewy (CHWY) $8.37B, Global Innovative Platforms (GIPL) $24.88M, Neogen (NEOG) $2.65B.

Which company is growing faster?

Chewy (CHWY) grew revenue fastest over the trailing twelve months: Chewy (CHWY) +5.9%, Neogen (NEOG) -0.3%.

Which company is more profitable?

Chewy (CHWY) has the highest net margin (Chewy (CHWY) 2.1%, Global Innovative Platforms (GIPL) -361.7%, Neogen (NEOG) -6.3%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Chewy (CHWY) -37.9%, Global Innovative Platforms (GIPL) -37.5%, Neogen (NEOG) +100.8%. Over five years, Neogen (NEOG) compounded fastest (Chewy (CHWY) -21.6%/yr, Global Innovative Platforms (GIPL) -36.9%/yr, Neogen (NEOG) -21.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Chewy (CHWY) has been the steadiest (Chewy (CHWY) 47.2%, Global Innovative Platforms (GIPL) 271.4%, Neogen (NEOG) 55.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CHWY, GIPL and NEOG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Chewy (CHWY) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.